Private Equity in Orthopedics: What Surgeon-Owners Need to Know (2026)

Private equity firms have made orthopedic surgery one of their most active targets in physician practice acquisition. Understanding how these deals work — and what they mean for your financial future — is now a core competency for any ortho practice owner.

Why private equity is targeting orthopedics

Orthopedic surgery has structural characteristics that make it attractive to financial acquirers in ways that most other specialties don't:

• High procedure volume and reimbursement. Spine, joint replacement, and sports medicine generate some of the highest reimbursement per wRVU in medicine. Total joint arthroplasty at an ASC, for example, generates $6,000–$14,000 in facility fees per case that a surgeon-owned ASC captures and a hospital retains.
• CMS outpatient migration. CMS has moved total knee arthroplasty, total hip arthroplasty, and dozens of spine procedures from inpatient-only to outpatient-eligible since 2020. This dramatically increased ASC revenue potential — the exact assets PE firms want to consolidate.
• Fragmented market ripe for roll-up. Orthopedic surgery is dominated by independent or small-group private practices. PE can acquire 10–25 practices in a market, centralize administrative overhead, and sell the consolidated platform to a larger PE fund or a health system at a higher multiple than the individual pieces commanded.
• Durable demand. Joint replacement and spine surgery demand is growing with an aging population. Unlike tech sectors, orthopedic surgery volume doesn't go to zero in a recession — it defers by 12–24 months at most.

How PE deals in orthopedics are structured

Most PE acquisitions of orthopedic practices use a Management Services Organization (MSO) structure. This exists because most states prohibit corporate practice of medicine — meaning a PE-owned entity cannot directly employ physicians or own a medical practice. The workaround:

1. The PE firm acquires (or forms) an MSO that handles billing, HR, IT, purchasing, credentialing, and administrative functions.
2. The MSO contracts with the physician group under a long-term management agreement (typically 30–40 years, automatically renewable).
3. The physician group retains nominal ownership of the medical practice but is contractually obligated to pay the MSO a "management fee" that effectively transfers most economic value to the PE entity.
4. The surgeon-owners retain a rollover equity stake — typically 20–30% of the new MSO entity — alongside the PE fund.

Some deals are structured as outright asset purchases rather than MSO arrangements, particularly in states with more permissive corporate practice rules. The financial mechanics are similar but the legal wrapper differs. Have a healthcare M&A attorney — not a generalist M&A attorney — review the structure before you sign anything.

The financial picture: reading a PE term sheet

EBITDA multiples

The headline number in a PE offer is the enterprise value, usually expressed as a multiple of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA).

The multiple at which your practice is valued depends heavily on: practice EBITDA margin (40%+ is attractive), subspecialty mix (spine > TJA > sports), ASC ownership (dramatically increases value), payer mix (commercial > Medicare > Medicaid), and whether the PE firm is acquiring a platform or doing an add-on to an existing portfolio.

EBITDA normalization: the number that matters

PE firms normalize EBITDA to remove one-time items and adjust surgeon compensation to "market rate" — which is usually lower than what you actually earn. The adjustment has two effects:

• Compensation addback. If you're paying yourself $900K but market-rate physician cost is $600K, PE normalizes by adding $300K back to EBITDA. This increases the enterprise value number but may also set your post-close compensation at $600K.
• One-time expense addbacks. Legal fees, one-time equipment purchases, owner perks billed through the practice — all added back, increasing EBITDA and thus enterprise value.

The normalized EBITDA is the foundation of your deal. Make sure your financial advisor and attorney review the normalization schedule carefully — it's a negotiating surface as much as a calculation.

Net proceeds: what you actually keep

At closing, proceeds flow roughly as follows:

• Gross enterprise value = Normalized EBITDA × multiple
• Less: practice debt, seller transaction costs (legal, tax advisory, quality of earnings), and any working capital adjustment
• = Net proceeds available
• Cash at close = approximately 70–80% of net proceeds (the portion you receive immediately)
• Rollover equity = approximately 20–30% of net proceeds (equity in the new MSO platform)

Federal tax on the cash-at-close portion (long-term capital gains): 23.8% (20% capital gains + 3.8% Net Investment Income Tax) for surgeons above the $600,050 MFJ threshold.¹ Add state capital gains tax — California at 13.3%, Texas at 0%, New York at 8.82%. Effective combined federal + state rate can reach 33–37% in high-tax states.

Use our Practice Sale Calculator to model your specific proceeds after taxes based on your EBITDA, multiple, deal structure, and state.

Rollover equity: the second bite of the apple

Rollover equity is the share of the new PE platform you retain after closing. If PE acquires 75% of the MSO and you roll 25%, your rollover stake has an implied value of approximately 25% × enterprise value at closing. But you cannot sell this stake until the PE firm exits — typically in 5–7 years via another sale or an IPO.

The thesis: when the PE firm exits, it expects to sell the platform at a higher multiple than it paid. If they paid 8× for your group as a standalone practice, the consolidated 15-group ortho platform might sell for 12–14× — creating significant appreciation in your rollover equity. Surgeons who sold for 8× and rolled 25% into a platform that sold for 13× three years later effectively received a large second payment in addition to their initial cash.

The risk: PE exits don't always succeed on timeline or at higher multiples. Market conditions can compress multiples. Platform integration can create operational problems. Your rollover equity is illiquid and subordinate to the PE fund's preferred return in a downside scenario.

Rollover equity second-bite calculator

Enter your deal parameters to see the potential second-bite value compared to your first-bite proceeds.

What changes post-acquisition

This is where surgeon expectations often diverge from reality. Financially, PE acquisitions typically offer:

• Compensation restructuring. You may have been paying yourself $900K through a combination of W-2, distributions, and perks. Post-close, you receive a physician employment agreement with a productivity-based comp formula — often lower than pre-acquisition all-in comp in the first 1–3 years while the new model stabilizes.
• Reduced administrative ownership. Billing, HR, IT, and contracting move to the MSO. For most surgeons, this is a net positive — fewer nights reviewing AR aging reports. For those who built administrative capability as a competitive advantage, it may feel like a loss of control.
• Quality and compliance reporting overhead. PE-backed platforms face heightened regulatory scrutiny. Expect MIPS, payer quality reporting, and internal benchmarking against portfolio peers to become more prominent.
• ASC governance changes. If your group owns an ASC, the acquisition will likely trigger a restructuring of ASC governance. PE may seek to acquire a majority stake in the ASC entity or restructure the management arrangement. Understand exactly how your ASC equity is treated before you sign.
• Expansion pressure. PE firms grow revenue by adding surgeons and locations. You may be expected to participate in recruiting, onboarding, or new site development as part of your post-acquisition role.

Six red flags in PE LOIs and purchase agreements

A decision framework: when PE makes financial sense

The financial case for a PE sale is strongest when:

• You have 5–15 years until retirement, and the first-bite cash significantly accelerates your FI timeline even if the second bite underwhelms.
• You own significant ASC equity, which increases your enterprise value substantially vs clinical income alone.
• The offer multiple (8–12×) reflects genuine premium relative to what a physician buyer would pay (2–5×) — you're capturing the difference.
• You've done substantial pre-sale tax planning: Roth conversions in prior years, QOZ investment setup, charitable structures staged for the closing year.
• Your health or energy trajectory suggests you want to reduce administrative burden before clinical volume naturally declines.

The financial case is weaker when:

• You're 20+ years from retirement and the non-compete duration restricts your optionality significantly.
• You have a high-growth ASC equity stake that may compound faster independently than rollover equity in a PE platform.
• The PE buyer is normalizing your comp down significantly — meaning post-close employment income is substantially lower than you currently earn, and you bear the income loss while the rollover equity matures.
• The offered multiple is below 7×, suggesting you're being acquired as a "platform" (lower price) rather than a premium add-on to an established group.

Pre-sale financial moves to make before closing

The year before a PE transaction closes is the most valuable window for financial planning. Key actions:

• Roth conversion before the sale year. The sale-year MAGI spike will push all income into the 37% ordinary income bracket (for W-2 income) and trigger maximum IRMAA for two years. Convert pre-tax retirement accounts in the year before closing, not after. See our Roth conversion strategy guide.
• Charitable giving in the closing year. A $3–10M capital gain event is the optimal time to fund a Donor Advised Fund with appreciated assets, pre-pay 5 years of charitable goals, and claim the itemized deduction at the 37% rate. The OBBBA 0.5% AGI floor and itemized deduction haircut for top earners make this timing more important, not less.
• Qualified Opportunity Zone setup. If you have a capital gain from the practice or ASC sale, a QOZ investment defers that gain until 2026 recognition (OZ 1.0 deadline Dec 31, 2026) or indefinitely under OZ 2.0 for new investments post-2027. See our QOZ guide.
• Practice sale vs separate real estate. If you own your medical office building, the building and practice are separate assets for tax purposes. A 1031 exchange on the real estate sale can defer that capital gain even when the practice sale is taxable. These require separate legal and tax structures — don't close them simultaneously without planning the sequencing.
• Estate planning before a liquidity event. At $15M+ estates (OBBBA permanent exemption), a valuation discount strategy on practice interests before the sale can reduce taxable estate significantly. This requires completing transfers before the LOI is signed — FMV is harder to discount once a PE offer is on the table.

How a financial advisor helps with a PE deal

Most orthopedic surgeons who have navigated PE deals describe three stages of regret: (1) not having a financial advisor before signing, (2) learning about the tax implications only after closing, and (3) not having a plan for the liquidity when it arrived.

An advisor who specializes in orthopedic practice sales can model the offer against your specific retirement timeline, run the tax scenarios across deal structures, sequence the pre-close charitable and Roth moves, coordinate with your M&A attorney on compensation normalization, and help you evaluate the rollover equity assumptions before you commit.

See our guide to choosing a financial advisor for the specific expertise signals to look for. For a deal-specific resource, see our complete practice sale guide, which covers the transaction mechanics and tax treatment in detail.

1. IRS Rev. Proc. 2025-32 — 2026 capital gains thresholds; IRC § 1411 Net Investment Income Tax (3.8% on net investment income above $200K single / $250K MFJ, not indexed for inflation).
2. MGMA 2025 Physician Compensation and Production Report — 2024 actuals for orthopedic surgeon compensation by subspecialty and employment model.
3. 42 C.F.R. § 1001.952(r) — OIG Anti-Kickback Statute safe harbor for ASC investment interests; physician-owned ASC ownership criteria and investment percentage requirements.
4. CMS Final Rule CY 2024 Outpatient Prospective Payment System — expansion of ASC-covered surgical procedures list including TKA and THA (effective January 2020), spinal fusion procedures (ongoing expansion 2023–2026).
5. Values verified as of June 2026. Federal LTCG rate 20% + NIIT 3.8% = 23.8% combined for taxpayers above $600,050 MFJ threshold per IRS Rev. Proc. 2025-32. State rates vary; consult a tax advisor for your specific state.